Reviving Sri Lanka’s Pharma Sector: A Strategic Partnership with India Could Be the Game Changer

Sri Lanka’s pharmaceutical sector is facing an unprecedented crisis. A deadly combination of foreign exchange shortages, inflation, and overdependence on imports—currently covering 80–85% of national pharmaceutical needs—has triggered persistent drug shortages across the country. From essential antibiotics to cancer treatments, the island nation has seen stockouts of over 180 life-saving medicines, putting its citizens’ health and public confidence in jeopardy. Local manufacturing, once gaining momentum under government buyback guarantees, is now at risk of collapsing due to expiring agreements and policy uncertainty. In the midst of this turmoil, patients are left vulnerable, hospitals are under-equipped, and the trust in healthcare institutions is wearing thin.

This crisis, however, is not just the result of economic hardship—it is rooted in systemic governance failures. An inefficient drug regulatory system, opaque procurement procedures, unreliable pricing mechanisms, and inconsistent government policy have collectively discouraged both local and foreign pharmaceutical investment. While India supplies nearly half of Sri Lanka’s imported pharmaceuticals, its pharmaceutical companies remain hesitant to deepen their engagement due to regulatory bottlenecks, bureaucratic delays, rigid pricing controls, and lack of long-term policy clarity.

In stark contrast, India has emerged as the “Pharmacy of the World.” Backed by the landmark Patents Act of 1970, strategic industrial policies, and a skilled workforce, India developed a thriving pharmaceutical sector producing over 60,000 generic medicines and exporting to over 200 countries. Indian pharma companies are now global leaders in producing affordable, high-quality generics and vaccines—supplying 40% of generics used in the U.S. and 25% of the UK’s medicine supply. Low production costs, robust R&D, and policy support like the Production Linked Incentive (PLI) scheme have made Indian medicine accessible not only in high-income countries but also to millions in developing regions.

Given this context, Sri Lanka’s best opportunity to resolve its perennial medicine crisis lies in strategically integrating India’s pharmaceutical expertise into its own medical supply chain. This is more than a short-term fix—it’s a chance to create a long-term, self-sustaining solution. If India is invited not merely as a supplier but as a manufacturing partner, with incentives to set up local production units, Sri Lanka could transform its pharma sector. Such a shift would enhance local medicine availability, generate employment, develop skills, and eventually position Sri Lanka as a regional manufacturing hub.

The government must provide clear policy direction: extend and formalize buyback agreements, designate pharmaceutical zones like those in Hambantota or Kalutara, and offer tax holidays and regulatory fast-tracking to attract Indian manufacturers. Over time, Indian pharma firms can begin producing not only for Sri Lankan consumption but also for export to Africa, ASEAN, and other SAARC markets. This export potential, coupled with reduced import bills, can strengthen Sri Lanka’s foreign reserves—at a time when global trade dynamics are shifting, and nations like the U.S. under President Trump have hinted at imposing differential tariffs.

This vision is not just aspirational—it’s practical. Precedents already exist, such as Indian partnerships to manufacture cancer drugs in Sri Lanka and Malaysia’s investment in dedicated pharma zones. Indian companies stand to benefit by diversifying production, tapping into Sri Lanka’s trade treaties, and leveraging its proximity to key export markets. Patients would benefit from more reliable access to essential medicines, and the economy would gain resilience through FDI, technology transfer, and export revenue.

In short, a deep pharmaceutical partnership with India could be the game changer Sri Lanka needs. It offers a rare win-win opportunity—ensuring medicine security for Sri Lanka while allowing Indian pharma to expand its regional footprint. With clear policy action and strategic intent, Sri Lanka can convert its health crisis into a transformative industrial opportunity.